Hereditary Testing Services Market: Introduction

Hereditary testing is usually referred to as genetic testing or DNA testing. Hereditary testing is employed to spot alterations in the DNA sequence that correlate with a disease or higher risk to develop a disease. This kind of test is often used for diagnosis before any symptoms of the disease are recognizable in order to work out the personal risk for certain multifactorial diseases. Thus, the results of hereditary testing can have far-reaching effects on a person's life.

Hereditary testing can provide important information for diagnosis, treatment, and prevention of illness; however, there are limitations. For instance, a positive result from DNA testing in a healthy individual doesn't generally mean that he would develop a disease, while in some situations, a negative result doesn't guarantee that the individual won't have a particular disorder.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=79639

Key Drivers, Restraints, and Opportunities of Hereditary Testing Services Market

The global hereditary testing market is estimated to expand significantly in the near future, due to a rise in incidence of hereditary disorders and cancer and a rise in awareness & acceptance of personalized medicines. For instance, hereditary testing has been widely utilized in pharmacogenomics, also referred to as drug-gene testing. Additionally, advancements in hereditary testing techniques are expected to boost the hereditary testing market during the forecast period. However, standardization concerns of hereditary testing-based diagnostics and stringent regulatory requirements for product approvals are anticipated to hamper the hereditary testing market during the forecast period. Conversely, untapped emerging markets in developing countries are expected to offer significant opportunities for market players. For instance, healthcare systems in developing countries such as Brazil, India, and China have witnessed a significant increase in investments in healthcare and infrastructure, which boosts the demand for hereditary testing in the region.

Technological advancements in hereditary testing are likely to boost the global market during the forecast period. Advances in sequencing techniques have reduced the sequencing time and cost of hereditary testing. For instance, microarrays substantially reduce the sequencing time by utilizing microchips. These microchips employ fluorescein to spot mutations within the chromosomes. Furthermore, innovations such as exome sequencing and next-generation sequencing have reduced the cost of hereditary testing. Hence, technological advancements are projected to propel the global hereditary testing market during the forecast period.

Request for Analysis of COVID-19 Impact on Hereditary Testing Services Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=79639

North America to expand significantly during forecast period

North America is projected to dominate the global hereditary testing services market during the forecast period. Increased demand for hereditary testing to understand ancestry, a rise in the demand for in-vitro fertilization (IVF), and pre-implantation testing are key factors augmenting the share held by the region. Technological advancements, presence of key players, launch of new products, the demand of diagnostics for cancer detection, and rise in prevalence and incidences of autoimmune, infectious diseases in the region are major factors driving the market in the region.

The hereditary testing services market in Asia Pacific is anticipated to expand at a notable growth rate during the forecast period. Increase in patient burden suffering from chronic diseases and recent mergers & acquisitions among key players offering hereditary testing and services are estimated to propel the market in the Asia Pacific region during forecast period.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=79639

Top Companies in Hereditary Testing Services Market

The global hereditary testing services market is consolidated in terms of the number of players. Key players in the global hereditary testing services market include

Pre book Hereditary Testing Services Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=79639&ltype=S

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit BhiseyTransparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

More here:
Hereditary Testing Services Market: Advancements in hereditary testing techniques are expected to boost the market - BioSpace

Study Demonstrates Superior Performance of ThyGeNEXT and ThyraMIR vs. Other Molecular Tests

PARSIPPANY, NJ, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that the study entitled Multiplatform molecular test performance in indeterminate thyroid nodules was published on-line in the peer-reviewed journal, Diagnostic Cytopathology. This paper represents the culmination of a multi-center, blinded clinical validation study in which gold standard unanimous histopathology consensus diagnosis was utilized. The study results demonstrate that ThyGeNEXT + ThyraMIR combination testing yield the highest positive predictive value (PPV) and similar negative predictive value (NPV) in comparison to other marketed tests for the same indication.

Approximately 25% of thyroid nodule fine needle aspirates (FNAs) have cytology that is indeterminate for malignant disease. Ancillary multiplatform testing with ThyGeNEXT and ThyraMIR assists in the accurate risk stratification of these FNAs, ultimately helping to distinguish patients who are more likely to benefit from conservative management from those who are more likely to benefit from surgical intervention.

The published manuscript is the first to report the performance characteristics of combination ThyGeNEXT and ThyraMIR testing in a blinded multicenter study. ThyGeNEXT is the companys most recent next generation sequencing based test that was expanded from its original version (ThyGenX) to include markers that have targeted therapies and those that can identify aggressive forms of thyroid cancer. The study demonstrates that combination testing with ThyGeNEXT and ThyraMIR has both high sensitivity (95%) and high specificity (90%) for identifying disease. It also highlights the important role that ThyraMIRthe companys proprietary microRNA risk classifiercan play in helping to identify malignancy in nodules where single platform mutation panels commonly detect mutations that by themselves have suboptimal PPV for malignancy.

According to Jack Stover, President and CEO of Interpace, The results of this independent study reported in a well-respected journal reflect the strong clinical performance and overall value of our combined thyroid assays in helping physicians manage their patients with potential thyroid cancer.

About ThyGeNEXT and ThyraMIR

ThyGeNEXT is Interpaces most recent next generation sequencing test that was expanded from its original version (ThyGenX) to include markers that have targeted therapies and those that can identify aggressive forms of thyroid cancer.

ThyGeNEXT utilizes state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer, as well as Medullary Thyroid Carcinoma. ThyraMIR is the first microRNA gene expression classifier. MicroRNAs are small, non-coding RNAs that bind to messenger RNA and regulate expression of genes involved in human cancers, including every subtype of thyroid cancer. ThyraMIR measures the expression of 10 microRNAs. Both ThyGeNEXT and ThyraMIR are covered by Medicare and most Commercial insurers.

According to the American Thyroid Association, approximately 20% of the 525,000 thyroid fine needle aspirations (FNAs) performed on an annual basis in the U.S. are indeterminate for malignancy based on standard cytological evaluation, and thus are candidates for ThyGeNEXT and ThyraMIR.

ThyGeNEXT and ThyraMIR reflex testing yields high predictive value in determining the presence and absence of cancer in thyroid nodules. The combination of both tests can improve risk stratification and surgical decision-making when standard cytopathology does not provide a clear diagnosis.

About Interpace Biosciences

Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Clinical services, through Interpace Diagnostics, provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX that differentiates lung cancer of primary vs. metastatic origin. In addition, BarreGEN for Barretts Esophagus, is currently in a clinical evaluation program whereby we gather information from physicians using BarreGEN to assist us in positioning the product for full launch, partnering and potentially supporting reimbursement with payers.

Pharma services, through Interpace Pharma Solutions, provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries. Pharma services also advance personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

For more information, please visit Interpace Biosciences website at http://www.interpace.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Companys future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including believes, estimates, anticipates, expects, plans, projects, intends, potential, may, could, might, will, should, approximately or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Companys control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Companys actual results to be materially different from those expressed or implied by any forward-looking statement. Additionally, all forward-looking statements are subject to the Risk Factors detailed from time to time in the Companys most recent Annual Report on Form 10-K filed on April 22, 2020, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contacts: Investor RelationsEdison Group Joseph Green/ Megan Paul(646) 653-7030 / 7034jgreen@edisongroup.com/ mpaul@edisongroup.com

Read the original post:
Interpace Biosciences Announces Results of Seminal Clinical Validation Study for Thyroid Assays - GlobeNewswire

The large scale Pharmacogenomics marketing report provides CAGR values along with its fluctuations for the specific forecast period. This persuasive marketing report has been generated by taking into thought several aspects of marketing research and analysis that can be listed as market size estimations, market dynamics, company & market best practices, entry level marketing strategies, positioning and segmentations, competitive landscaping, opportunity analysis, economic forecasting, industry-specific technology solutions, roadmap analysis, targeting key buying criteria & in-depth benchmarking of vendor offerings. This Pharmacogenomics market research report is of great importance for superior decision making and achieving competitive advantage.

Get FREE Sample PDF (including COVID19 Impact Analysis) of Market Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-pharmacogenomics-market&rp

Market Analysis and Insights: Global Pharmacogenomics Market

Global pharmacogenomics market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. Emerging markets and huge investment in research and development are the factors responsible for the growth of this market.

The major players covered in the globalpharmacogenomics marketareAbbott, AstraZeneca, Bayer AG, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, OPKO Health, Inc, Teva Pharmaceutical Industries Ltd, Myriad Genetics, Inc., QIAGEN,OneOme, LLC, Illumina, Inc, Empire Genomics, LLC, and Dynamic DNA Laboratories among others.

The factors primarily driven the growth of pharmacogenomics market are high adoption of personalized therapy. In addition, high prevalence of life-threatening disorders globally and improvement in molecular techniques for developing pharmacogenomics-based therapeutics are some of the impacting factors for the growth of this market. Nevertheless, less trained expertise or technically skilled professionals and coupled with difficulties in terracing gene variation that significantly affects the drug response are the factors that hinder the growth of this market.

Pharmacogenomics is the study of how human genes affect the way bodies responds to the medications. It is emerging field which combines the pharmacology and genomics to develop highly effective and right or safe medicines tailored to the patients genetic makeup.

Pharmacogenomics market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographical expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Pharmacogenomics Market Scope and Market Size

Pharmacogenomics market is segmented on the basis of technology, application, end-users and distribution channel.

Pharmacogenomics Market Country Level Analysis

Pharmacogenomics market is analysed and market size information is provided by country, technology, application, end-users and distribution channel as referenced above.

The countries covered in the global pharmacogenomics market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, in the Asia-Pacific, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

North America has been witnessing a positive growth throughout the forecasted period due to the presence of refined healthcare expenditure and increased patient awareness level as well as preference personalized medicines. Europe is considered a second largest growing regional segment owing to the growing geriatric population and rising prevalence of chronic diseases.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Pharmacogenomics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Pharmacogenomics Market Share Analysis

Pharmacogenomics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies focus related to global pharmacogenomics market.

Customization Available: Global Pharmacogenomics Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-pharmacogenomics-market&rp

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us :

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475Mail:Corporatesales@databridgemarketresearch.com

More:
Pharmacogenomics Market 2020-2027 Incredible Possibilities, Growth With Industry Study, Detailed Analysis || Leading Players Abbott, AstraZeneca,...

The birth of the "genomic era" is marked by the completion of the Human Genome Project in 2003, whereby next-generation sequencing whittled down the complexity of a human being to a code of letters. Advances in high-throughput technologies have added further data, exploring the interactions between genes and the environment and vice versa.

As our knowledge of life at the molecular level continues to evolve, it becomes increasingly apparent that, to effectively understand and manage human health, a shift from a one-size-fits-all approach to focusing on humans at the individual level is required. We're already seeing the "promise" of personalized medicine being delivered in areas such as pharmacogenomics and cancer immunotherapy, but the insights garnered from omic sciences such as metabolomics are also impacting the way we think about nutrition.

A number of noncommunicable diseases are linked to nutrition, including diabetes, cancer and cardiovascular disease. A variety of different dietary interventions have been proposed for the prevention and treatment of such diseases as an alternative to pharmacological medication. But we now know that individual differences in our biochemistry, metabolism and genetics all impact our response to nutrition, and prescribing the same intervention broadly will not produce the same result for each unique patient.

So how do we use the information obtained from metabolomics approaches to move towards personalized nutrition? That's the focus of this interview with Professor Lorraine Brennan, Conway Fellow and principal investigator at the University College Dublin Institute of Food and Health where she leads the Nutrition, Biomarkers and Health research group.

Molly Campbell (MC): Why is it important that humans move towards a personalized nutrition approach, as opposed to a "one-size-fits-all" approach?Lorraine Brennan (LB): The realization that there are huge inter-individual responses to dietary interventions is pushing us to re-think our concepts. While dietary recommendations may be a good diet for all, they may not represent the optimal diet for all. To take into account the individual, we have to start understanding individual responses and metabolomics has huge potential in this regard. The emergence of precision nutrition will help pave the way forward for the development of more tailored dietary advice.MC: In your opinion, what have been some of the most exciting developments in metabolomics and nutrition research over the past few years?LB: Metabolomics has had a major impact in nutrition research. The whole area of dietary biomarkers has completely evolved as a result of developments in metabolomics. In particular, there is growing interest in the use of objective biomarkers of food intake and metabolomics offers a route into the identification and development of novel biomarkers. The further development of these biomarkers should allow us to develop more accurate methods for assessment of food intake. With respect to understanding the mechanisms underpinning the health benefits of certain diets metabolomics has played a key role both in intervention studies and also in epidemiology studies. Continued expansion of the metabolome coverage offers great opportunities for nutrition research.MC: Your laboratory focuses on the development of metabolomics for nutritional research. Can you please tell us about your key focus points within this field?LB: I have a large program of research focussed on the identification, development and use of food intake biomarkers. One of the key challenges we face in the field of human nutrition is our poor ability to assess dietary intake. Our current methods have a number of well-established limitations and food intake biomarkers offer a new and objective approach. We are working on development of new biomarkers and also on working out how to use such biomarkers in nutrition research. We are also working on precision nutrition and new methods for delivering personalized dietary advice to individuals.

MC: You recently published a review paper outlining metabotyping and its role in nutrition research. Please can you tell us more about metabotypes what they are and how they can be used to identify an individual's response to a dietary intervention?

LB: Metabotypes are groups of individuals defined on the basis of their similarities in metabolic profile, which in turn results from an interaction between lifestyle, gut microbiome, genes and environmental factors. With respect to dietary interventions application of a metabotype approach has led to the identification of groups of subjects with distinct metabolic phenotypes/metabotypes and unique responses. The metabotype approach represents a tool through which we can start to understand individual responses to interventions, with the ultimate goal being to employ it for the delivery of personalized nutrition.

MC: What key technologies do you utilize in your lab? Are there any challenges that come with using such methods?

LB: We use nuclear magnetic resonance spectroscopy and mass spectrometry-based metabolomics approaches. We find that both approaches complement each other. One of the key challenges for us is metabolite identification. As we are interested in metabolites that originate in food, many of the metabolites we wish to identify are not present in databases. As a consequence, we put a huge effort into compound identification. I think that we need to work together as a community to improve this and make significant breakthroughs. Cross-lab collaborations could make significant advancements in this area.MC: In your opinion, what is the greatest barrier to introducing a personalized nutrition approach on a global scale?

LB: We are still building the evidence base for personalized nutrition. More research is needed to understand the responses to diet. The results to date are very encouraging, and more research is needed to define the optimal diet at an individual level.Professor Lorraine Brennan was speaking to Molly Campbell, Science Writer, Technology Networks.

More here:
What's Your (Metabo)Type? Metabolomics and the Pursuit of Personalized Nutrition - Technology Networks

The global gene amplification technologies market is poised for growth on the back of rising demand for genetic information for identifying and mapping all the genes of human genome. The market is slated to reach a valuation of US$2.2 bn in 2017.

View Report :https://www.transparencymarketresearch.com/gene-amplification-technologies-market.html

The report presents the latest technological developments in the field and a growth map for the coming years. It also explains its effect on market dynamics and leverages SWOT analysis of major industry segments

Gene Amplification Technologies Market: Trends and Opportunities

The single-most important growth driver for gene amplification technologies market has been the Human Genome Projects (HGP). It is an international, collaborative research effort to sequence all the chemical base pairs that form the DNA of the speciesHomo sapiens. Another major growth driver is molecular diagnostics that helps uncover specific sequences in DNA or RNA to check if they are associated with any disease. It is clinically used for oncology, coagulation, genetic disease screening, infectious diseases, pharmacogenomics, and human leukocyte antigen typing. Development in clinical diagnostic tools, is also expected to boost the growth of the gene amplification technologies market.

Get Brochure of the Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=426

Other factors driving the gene amplification technologiesmarket are the increasing focus on research and development in the field of molecular diagnostics, drug discovery, genetic testing, toxicology, environmental monitoring, animal husbandry, bioremediation, forensics, and quality control in the food industry. Gene amplification technologies, however, are expensive to develop. This has, to some degree, served to counter the growth of the market.

Gene Amplification Technologies Market: Technology and Application-wise Segmentation

There are various ways in which the gene amplification technologies market can be segmented. For example, based on technology, it can be divided into the following: Isothermal DNA amplification, target amplification,cycling temperature DNA amplification, isothermal signal amplification, linear gene amplification, cycling temperature signal gene amplification, and exponential gene amplification.By application, the market can be divided into identity, forensics, identity, paternity, food safety, medical, veterinary, and agri-diagnostics. Medical and forensics are the two largest segments in terms of application.

REQUEST FOR COVID19 IMPACT ANALYSIS https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=426

Gene Amplification Technologies Market: Region-wise Outlook

Geographically the market for gene amplification technologies can be divided into Europe, Asia Pacific, North America, Latin America, and Middle East and Africa. North America has exhibited stellar growth so far, with maximum revenue raked in. This has been possible on account of high allocations for healthcare infrastructure, and research and development for genetic testing, diagnostics and detection of critical diseases all of which have yielded unprecedented technological advancements. North America is expected to remain the leading market in the upcoming years too, because of continued government funding of research and infrastructure.

Asia Pacific would also put up a good showing, it is predicted. This is mainly due to governments of various nations in the region increasingly focusing on upgrading healthcare infrastructure. Fast developing economies such as China and India are expected to see higher growth rates because of increased abundant manpower of skilled workers who can carry out proper research, lower cost, and supportive government policies.

Read our Case study at :https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

Players in the Gene Amplification Technologies Market

Some of the leading entities in the gene amplification technologies market that have been profiled in the report are: Chugai Biopharmaceuticals Inc., Abbott Laboratories, Cepheid, Agilent Technologies, ID Biomedical Corporation, Molecular Sensing PLC, Orchid Biosciences Inc., Rubicon Genomics, and U.S. Genomics.

More Trending Reports by Transparency Market Research 1.http://www.prnewswire.com/news-releases/thrust-on-pharmaceutical-sector-to-develop-novel-drugs-for-clinical-conditions-propels-pharmaceutical-excipients-market-transparency-market-research-301017102.html

2.https://www.biospace.com/article/electrophysiology-devices-market-rising-incidences-of-cardiac-arrhythmias-expected-to-propel-the-market/

Read the original here:
Gene Amplification Technologies Market Trends by Manufacturers, States, Type and Application, Forecast to 2016 2024 - The Think Curiouser

The analysis of GlobalPharmacogenomics Marketincludes market size, upstream situation, market segmentation, price & cost and industry environment. In addition, the report outlines the factors driving industry growth and the description of market channels. The report begins from overview of industrial chain structure, and describes the upstream. Besides, the report analyses market size and forecast in different geographies, type and end-use segment, in addition, the report introduces market competition overview among the major companies and companies profiles, besides, market price and channel features are covered in the report.

Feel free to contact us for any inquiry, Download PDF Sample Copy of Pharmacogenomics Market @https://www.supplydemandmarketresearch.com/home/contact/1508770?ref=Sample-and-Brochure&toccode=SDMRHE1508770

According toSupply demand Market Research, ThePharmacogenomics MarketMarket 2020 Research offers an extensive analysis of key drivers, leading market players, key segments, and regions. Besides this, the experts have deeply studied different geographical areas and presented a competitive scenario to assist new entrants, leading market players, and investors to determine emerging economies. These insights offered in the report would benefit market players to formulate strategies for the future and gain a strong position in the global market.

A summary of the performance evaluation of the Pharmacogenomics Market is offered in this report. It also includes crucial information concerning to the key industry trends and projected growth rate of the said market. The study provides details regarding the growth avenues and hindering factors prevailing in the business space.

Asia Pacific pharmacogenomics market will grow by 10.3% annually with a total addressable market cap of $21.7 billion over 2020-2030 owing to the rising adoption of personalized medicine and usage of pharmacogenomics for drug discovery and development amid COVID-19 pandemic.

Highlighted with 35 tables and 49 figures, this 122-page report Asia Pacific Pharmacogenomics Market 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Country: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire Asia Pacific pharmacogenomics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects: Market Structure Growth Drivers Restraints and Challenges Emerging Product Trends & Market Opportunities Porters Fiver ForcesThe trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific pharmacogenomics market in every aspect of the classification from perspectives of Service, Technology, Application, End User, and Country.

Based on Service, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Genotyping SNP Identification Diagnostics Other Services

Based on Technology, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Polymerase Chain Reaction (PCR) Microarray Sequencing Electrophoresis Mass Spectrometry Other Technologies

Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Oncology Infectious Diseases Neurology/Psychiatry Cardiovascular Pain Management Other Applications

Based on End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Hospitals and Clinics Pharmaceutical Companies Research Institutes

Geographically, the following national/local markets are fully investigated: Japan China South Korea Australia India Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)Detailed analysis and annual revenue 2019-2030 are available for each key national market. The breakdown of key national markets by Service, Technology, and Application over the forecast years are also included.The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.Specifically, potential risks associated with investing in Asia Pacific pharmacogenomics market are assayed quantitatively and qualitatively through SDMRs Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.Key Players (this may not be a complete list and extra companies can be added upon request):23andMe, Inc.Abbott LaboratoriesAdmera Health, LLCAgena Biosciences, Inc.Astra Zeneca PLCBayer AGBecton, Dickinson and CompanyCancer Genetics, Inc.Dynamic DNA LaboratoriesEmpire Genomics LLCF. Hoffmann-La Roche LtdgeneOmbio Technologies Pvt Ltd.Genomic Health, Inc.Illumina, Inc.Laboratory Corporation of America HoldingsMyriad Genetics Inc.Oneome LLCOpko Health, Inc.Pathway Genomics CorporationQIAGEN N.V.Quest Diagnostics IncorporatedTeva Pharmaceuticals Industries Ltd.Thermo Fisher Scientific Inc.Transgenomic, Inc.(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Get More Information About Full Report/Talk to our Analyst Regarding Pharmacogenomics Market @https://www.supplydemandmarketresearch.com/home/contact/1508770?ref=Discount&toccode=SDMRHE1508770

This comprehensive report can be a guideline for the industry stakeholders that helps in analyzing the Pharmacogenomics Market and forecast of till 2024. This report aids to detection of the projected market size, market status, future predictions, growth prospect, main challenges of Pharmacogenomics Market by analyzing the segmentations.

In the following section, the report provides the Pharmacogenomics Market company outline, statements of the product, and performance values. With the support of the arithmetical study, the report demonstrates the complete international Pharmacogenomics Market market inclusive of amplitude, production, manufacturing value, loss/gain, Pharmacogenomics Market supply/demand and import/export. The Pharmacogenomics Market report is divided into key companies, by regions, and by various sectors such as application, type for the competitive landscape analyze.

About Us:

We have a strong network of high powered and experienced global consultants who have about 10+ years of experience in the specific industry to deliver quality research and analysis. Having such an experienced network, our services not only cater to the client who wants the basic reference of market numbers and related high growth areas in the demand side, but also we provide detailed and granular information using which the client can definitely plan the strategies with respect to both supply and demand side.

Contact Us:

SUPPLY DEMAND MARKET RESEARCH

Mr. Charles Lee

302-20 Misssisauga Valley Blvd, Missisauga,

L5A 3S1, Toronto, Canada

Phone Number: +12764775910

Email- [emailprotected]

See the original post:
Pharmacogenomics Market To Witness Robust Expansion Throughout The Forecast Period 2020- 2027 - The Daily Chronicle

Genetic variation may mediate the increased risk of cardiovascular disease (CVD) in chemotherapy-treated testicular cancer (TC) patients compared to the general population. Involved single nucleotide polymorphisms (SNPs) might differ from known CVD-associated SNPs in the general population. We performed an explorative genome-wide association study (GWAS) in TC patients. TC patients treated with platinum-based chemotherapy between 1977 and 2011, age 55 years at diagnosis, and 3 years relapse-free follow-up were genotyped. Association between SNPs and CVD occurrence during treatment or follow-up was analyzed. Data-driven Expression Prioritized Integration for Complex Trait (DEPICT) provided insight into enriched gene sets, i.e., biological themes. During a median follow-up of 11 years (range 3-37), CVD occurred in 53 (14%) of 375 genotyped patients. Based on 179 SNPs associated at p0.001, 141 independent genomic loci associated with CVD occurrence. Subsequent, DEPICT found ten biological themes, with the RAC2/RAC3 network (linked to endothelial activation) as the most prominent theme. Biology of this network was illustrated in a TC cohort (n=60) by increased circulating endothelial cells during chemotherapy. In conclusion, the ten observed biological themes highlight possible pathways involved in CVD in chemotherapy-treated TC patients. Insight in the genetic susceptibility to CVD in TC patients can aid future intervention strategies.

The pharmacogenomics journal. 2020 Oct 03 [Epub ahead of print]

Lars C Steggink, Hink Boer, Coby Meijer, Joop D Lefrandt, Leon W M M Terstappen, Rudolf S N Fehrmann, Jourik A Gietema

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands., Department of Internal Medicine, Division of Vascular Medicine, University Medical Center Groningen, University of Groningen, Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands., Medical Cell BioPhysics, University of Twente, Drienerlolaan 5, 7522 NB, Enschede, The Netherlands., Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands. .

PubMed http://www.ncbi.nlm.nih.gov/pubmed/33011741

Read the rest here:
Genome-wide association study of cardiovascular disease in testicular cancer patients treated with platinum-based chemotherapy. - UroToday

Market Study Report, LLC, has added a detailed study on the Veterinary Therapeutics market which provides a brief summary of the growth trends influencing the market. The report also includes significant insights pertaining to the profitability graph, market share, regional proliferation and SWOT analysis of this business vertical. The report further illustrates the status of key players in the competitive setting of the Veterinary Therapeutics market, while expanding on their corporate strategies and product offerings.

The latest research report on the Veterinary Therapeutics market assesses the major factors influencing industry growth with respect to the competitive dynamics and geographical reach. It also ensembles the challenges prevalent in this industry vertical and identifies opportunities that will further aid business expansion. Further, the report revisits all areas of the business to cover the impact of COVID-19 pandemic so as to assist stakeholders in devising new strategies and reinforcing their position in the market.

Request a sample Report of Veterinary Therapeutics Market at:https://www.marketstudyreport.com/request-a-sample/2908669?utm_source=msf&utm_medium=RV

Key pointers from COVID-19 impact analysis:

Important inclusions in the Veterinary Therapeutics market report:

Ask for Discount on Veterinary Therapeutics Market Report at:https://www.marketstudyreport.com/check-for-discount/2908669?utm_source=msf&utm_medium=RV

Regional scope:

TOC of Veterinary Therapeutics Market Report Includes:

The Report Answers the key Questions

For More Details On this Report: https://www.marketstudyreport.com/reports/global-veterinary-therapeutics-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

Related Reports:

1. Global HIV Therapeutics Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)Read More: https://www.marketstudyreport.com/reports/global-hiv-therapeutics-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

2. Global Pharmacogenomics (PGX) Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)Read More: https://www.marketstudyreport.com/reports/global-pharmacogenomics-pgx-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Read more:
Veterinary Therapeutics Market 2020 Analysis & Forecast to 2026 by Key Players, - News.MarketSizeForecasters.com

As the second wave of the coronavirus hits, Well Health Technologies(TSX:WELL) stock is seeing rapid growth. Technology has always been underappreciated and underutilized in primary care healthcare. But today, the coronavirus has brought its merits to light like never before. We now know two things for sure.

Firstly, today in this pandemic, we need technology in primary healthcare like never before. It is allowing us to access our doctors while maintaining distancing. Secondly, the benefits of technology in primary healthcare are multi-faceted. Technology will continue to transform and improve healthcare for the long haul.

Here are the reasons why WELL stockis a stock to buy.

Well Healths stock price has shot up in 2020. This is no surprise, as demand for telemedicine has skyrocketed in the pandemic. Well Healths revenue in the first six months of 2020 increased 40%. In 2019, Well Healths revenue increased 211%.

With a $938 million market capitalization and a rapidly growing healthcare asset base, Well Health continues to transform the primary healthcare industry. The company continues to acquire clinical and digital healthcare assets.

As the second wave hits, Well Healths clinics and services will be even more in demand. And the benefits of telemedicine will become more and more obvious. With this, Well Health stock will continue its rise.

Well Health has a fast-growing digital portfolio of healthcare assets. It has 2,000 clinics, over 10,000 supported general practitioners, and over 15 million registered patients. The companys clinic portfolio is also becoming more and more sizable. It has 19 wholly-owned clinics and approximately 180 doctors at these clinics.

The primary healthcare system is one of the last big industries that has yet to digitize. According to Well Health reports, the Canadian primary care industry is a $250 billion industry. Physician spending accounts for approximately 15.4%. The industry is plagued by underinvestment, fragmentation and a lack of technology.

Well Health aims to change this. The benefits are big and they are clear. Digital tools can increase operational efficiency. They can improve patient care. They can allow physicians to focus more on what matters.

Virtual care ensures easy access to doctors. This has been key in the coronavirus pandemic. It will be even more key as the second wave hits. Waiting room automation allows for shorter wait times for patients. These are examples of what technology can do. But there are also more significant advantages.

Precision medicine proposes customizing healthcare decisions, treatments, practices, and products to suit individual patient needs. It basically means identifying best approaches tailored for a specific patient. Genetic, environmental, and lifestyle factors all play a role in determining a patients treatment. We can easily see how a digital database of information on each patient is key for this purpose.

In the future, a digital database with patients DNA can take all this a step further. Pharmacogenomics is the study of how genes affect a persons response to particular drugs. A database that has genetic data, biological samples, and other health information will step up healthcare into a new age.

Well Health stock has so much going for it. It has a significant runway of growth ahead as it participates in the digitization of the healthcare system. Patient care is improving and primary care offices are becoming more efficient. WELL stock trades at just over $6.50 at the time of writing. It has risen 130% in the last three months. Expect more big increases in the short, medium, and long term.

Fool contributor Karen Thomas has no position in any of the stocks mentioned.

Visit link:
Why Well Health (TSX:WELL) Is the Stock to Buy as the 2nd COVID-19 Wave Hits - The Motley Fool Canada

InvestorPlace

With so much death and economic destruction wrought by the novel coronavirus, its hard to find the silver lining. But if there is one on Wall Street, its the rise of artificial intelligence stocks. Yes, there is the profitability angle from machine learning and other relevant technology facilitates. But this crisis has been a crash course in the sectors viability.Hopefully, we wont suffer a second wave like many European countries are experiencing because, you know, people can just get over themselves and wear a flipping mask in public. But even if we do succumb to a second round, eventually, this too shall pass. However, the return to some sense of normalcy will likely take time. Thus, we may depend on contactless platforms. Of course, this international emergency has provided an excellent arena for finetuning.As well, its becoming clear that the scale and acceleration of our globalized economy is more than human brains can handle. Yes, we are the ultimate innovative species (as far as I know). However, machines can now play a major role in alleviating most if not one day all of our menial tasks. That frees us up for greater and more meaningful innovations, which is the underlying ethos of artificial intelligence stocks.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThis isnt just techno-babble gibberish. For instance, the food supply chain was put under enormous stress during the peak of Covid-19. Well before the pandemic, many retailers partnered with AI programmers to develop enhanced forecasting and planning infrastructure. Now, this need has accelerated due to the baptism of fire. Therefore, these diverse artificial intelligence stocks could enjoy upside throughout this year and beyond.Apple (NASDAQ:AAPL)Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL)IBM (NYSE:IBM)Nvidia (NASDAQ:NVDA)Tencent (OTCMKTS:TCEHY)Match Group (NASDAQ:MTCH)Trade Desk (NASDAQ:TTD)The 7 Top Robinhood Stocks for OctoberFinally, not everything about AI has to be so serious. Since were conducting our business and personal affairs increasingly online, almost anything that we can think of, including love and dating, can benefit from the integration of man and machine. Since this dynamic is well under way, here are the seven artificial intelligence stocks from which you can profit.Apple (AAPL)Source: View Apart / Shutterstock.comAs the manufacturer of the now-iconic iPhone, Apple is more well known as a consumer electronics behemoth rather than an investment into artificial intelligence stocks. Certainly, the company can bank simply on the power of its globally recognized brand. However, what makes AAPL stock special is that management refuses to be satisfied with its prior accomplishments.As evidence, consider Apples foray into electric vehicles. At one point, rumors circulated that hundreds of people were developing a car, one that could possibly compete with Tesla (NASDAQ:TSLA). Nowadays, it appears that the consumer tech firm is focusing on developing software for self-driving cars. If thats the case, such a course would require significant innovations in AI, particularly machine learning.Theoretically, Apple has a lot of practice in this arena thanks to its wealth of consumer data. In addition, the company has forged consumer friendly applications, such as palm rejection technology. This nifty development allows the iPad to recognize the difference between a deliberate input with the Apple Pencil versus accidental contact with a part of the hand.Undoubtedly, most investors will buy AAPL stock for its ever-popular smart devices. However, those who are interested in artificial intelligence stocks should also give it serious consideration.Alphabet (GOOG, GOOGL)Source: BigTunaOnline / Shutterstock.comWhenever anyone talks about artificial intelligence stocks, Alphabet is one of the top names thats mentioned and for good reason. Essentially, Alphabets Google owns the internet. As of July 2020, Google dominated desktop search engines with an 87% global market share. With figures like that, youre bound to have a wealth of consumer data that other organizations can only dream about.And with search dominance comes its web advertisement-driven revenue channels. Corporations spend billions buying up Google ads because thats where the people are. In turn, Alphabet has gotten quite adept at utilizing its AI infrastructure to fine-tune what consumers want and just as importantly, when they want it. Additionally, thanks to its YouTube platform, Alphabet has years of valuable experience understanding and predicting consumer behavior.Therefore, while GOOGL stock is often the target of social and political criticism, I dont see the internet giant going anywhere but up over a long-term horizon.7 Internet of Things Stocks for Investing in InnovationPlus, what really makes Alphabet stand out is its penchant for relevant acquisitions. For example, its DeepMind subsidiary specializes in traffic prediction algorithms. Thats not just important for everyday convenience but also as a framework for smart city infrastructures. Therefore, if you want more AI in your portfolio, go get some GOOGL stock.IBM (IBM)Source: JHVEPhoto / Shutterstock.comAlthough artificial intelligence stocks represent one of the hottest segments on Wall Street, individual names tend to be well-known entities. As such, theyre not exactly what you would call undervalued as they typically have already garnered much investor sentiment.Well, IBM doesnt have that problem. As a legacy tech giant, Big Blue has struggled over the years to shed its image of yesteryear innovations. Instead, management has pivoted to many relevant markets, including cloud computing and cybersecurity. However, IBM stock is frustrating, even in this year where its down 10% while other tech firms are up big.Nevertheless, if you want to go against the grain with your artificial intelligence stocks, IBM offers the patient investor potentially significant upside. As you know, with its AI platform Watson, Big Blue has been helping multiple enterprises and industries maximize their efficiency. One particular area that Im intrigued in is healthcare.With the novel coronavirus having disrupted this sector, theres never been a more critical time for improved efficiencies. Here, IBM could make a conspicuously positive impact, reducing administrative friction so that medical professionals can spend less time on paperwork and more time helping patients. Having learned tough lessons from the new normal, the pandemic could help IBM stock regain its footing.Nvidia (NVDA)Source: Hairem / Shutterstock.comWhen you hear the brand Nvidia, most likely what comes to mind first is video games. And thats not a bad thing, believe me. Before the pandemic, video games, especially the rise of eSports, helped drive the bullish case for NVDA stock. During the lockdowns and the new normal, this entertainment platform helped while away the hours when other options were off the table.Despite its dominance in gaming, Nvidia would like to let you know that its one of the leaders in artificial intelligence stocks as well. The companys partnership with Walmart (NYSE:WMT) illustrates this relationship perfectly. As a big-box retailer, Walmart must make critical decisions all the time about their inventory: how much to buy, when to ship them out and to which stores, among countless other concerns.Fortunately, Walmart has advanced data analytics software that references back decades of data for hundreds of millions of products. But all that data processing requires sophisticated hardware otherwise, youre not going anywhere. Thats where Nvidia comes in with its graphics processors. Sure, theyre best known for their gaming applications, but they can do so much more.The 7 Best Semiconductor Stocks to Buy TodayNot surprisingly, NVDA stock has significant links to other burgeoning industries, such as self-driving technologies and the blockchain. Therefore, youll want to keep this on your short list of artificial intelligence stocks to buy.Tencent (TCEHY)Source: StreetVJ / Shutterstock.comTaking aside the politics, if you want to broaden your portfolio of artificial intelligence stocks, you should look at China. Companies like Tencent really are in an enviable position. For one, Tencents home market has blossomed into a technological powerhouse. Second, Chinas massive population means ample room for growth, increased connectivity and the biggest data goldmine.Further, Tencent has wide-reaching ambitions regarding its AI initiatives. As an internet content and social media network provider, the company is finetuning personalized advertisements and suggestions for its millions of users. In addition, Tencent is pursuing more serious endeavors, such as medical AI applications. Here, the idea is to use technology to help physicians detect and prevent the spread of disease.With the coronavirus having originated from China as President Trump reminds us every day this application seems very relevant for TCEHY stock.Of course, nothing can be divorced from politics these days and so it is with Tencent. As the owner of WeChat, the messaging/payments app has come under fire from the Trump administration. And that might mean TCEHY stock is on shaky ground, at least until we figure out who will run our nation on Nov. 3. Still, the opportunity for upside is tantalizing because of the aforementioned attributes of the home market.Match Group (MTCH)Source: ShutterstockInvariably, analyses of artificial intelligence stocks typically involve high-scale solutions. Over this list, weve covered the impact that AI can have on our purchasing decisions, interactions with machines, forecasting inventory demand and improving health outcomes. But AI doesnt have to be so serious. Instead, it can help with that age-old longing for love.Thats right, for those of who want to give Cupid an assist, online dating apps, such as those under the Match Group umbrella, may help accelerate your search for a soulmate. But what if Cupid needs help too? Increasingly, the mythical god has turned to artificial intelligence to help provide appropriate matchups.In a way, this is the probably the most ingenious use of AI. By now, many of these dating sites and apps have collected an enormous amount of behavioral data. Thats also due to the stigma of online dating fading away. Plus, with the novel coronavirus disrupting offline dating, Match is one of the viable places to go. That right there is a great reason to consider MTCH stock.10 ESG Stocks to Buy for a Brighter FutureBetter yet, Match is wising up to the power of AI to promote a safe dating environment. The company invested in Noonlight to provide safety features such as location tracking in case a meetup goes awry. Thats smart thinking, which should separate MTCH stock from other social networking investments.Trade Desk (TTD)Source: BrightSpace / Shutterstock.comWell before the pandemic, the cord-cutting phenomenon was placing increased pressure on traditional cable TV providers. With the advent of connected TV and streaming services, these innovations sparked never-before-seen capabilities, such as on-demand viewing. Instead of people revolving their lives around content scheduling (as in linear TV), the new generation of entertainment adapted to the individual.Following the coronavirus impact, the pressure to cut the cord intensified for many households. This was especially true during the early days of the crisis, when new content offerings were thin but the bills kept piling up. But pandemic or not, streaming and connected TV is here to stay. And that makes Trade Desk a relevant idea among artificial intelligence stocks.Primarily, the company utilizes AI algorithms to maximize advertisers return for their connected TV dollars. Thats much easier now because Trade Desk has access to a wealth of viewership data. As a result, its able to pinpoint which advertising strategies will work best, bolstering the narrative for TTD stock.Further, with live sports returning, Trade Desk may have an opportunity to evangelize its services. Because of the added cord-cutting pressures, the live sports streaming audience has probably increased significantly. That plays into the hands of TTD stock, where the underlying company can help advertisers plan for the possibility of games that go into overtime, which will likely feature a substantial uptick in engaged viewers.On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare.More From InvestorPlaceWhy Everyone Is Investing in 5G All WRONGAmericas #1 Stock Picker Reveals His Next 1,000% WinnerRevolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 CompanyCould Tiny Super Battery Kill Big Tech?The post 7 Artificial Intelligence Stocks to Buy for October appeared first on InvestorPlace.

Continued here:
Innovative Gx Laboratories Announces the Grand Opening of Its Molecular Diagnostic Laboratory in Texas - Yahoo Finance

Someday there will be an app on your smartphone that knows exactly what medicine will work best for you. It will warn you of your risk for developing certain diseases and offer a personalized plan for preventing them. It will even be able to determine your likelihood of passing on certain conditions to your unborn baby. Ultimately, it will increase your lifespan and help you enjoy a higher quality of life.

This will all be possible because of one thing: genomics.

To understand genomics, you first have to understand thedifference between genes and genomes.

Genomicsis the study of genomes specifically how your DNA functions and interacts within your body. Through genomics, scientists and researchers have sought to better understand how a persons genes interact with each other and with their environment.

Precision genomicstakes this one step further. Using genomic information, doctors can create more personalized healthcare options for individuals battling illness and disease.

Human beings are more alike than they are different. In fact,research showsthat humans are 99.9 percent identical in their genetic makeup. Understanding the remaining 0.1 percent holds the clues about detecting and preventing certain diseases.Thats where genomics comes in.

Genetic testing looks for inherited mutations in healthy cells.Genomic sequencinglooks at genetic mutations in unhealthy cells.Heres why that matters for your health:

In the past, if you were diagnosed with cancer, your doctor would most likely recommend a standard form of treatment that worked for most people. But these days, healthcare providers can provide acustom-fit treatmentthats based on your specific DNA. They do this by identifying mutations in certain cells.

Dr. Lincoln Nadauld,chief of precision health and academics at Intermountain Healthcare, put it simply. [Precision genomics] means picking treatments for patients with cancer based on DNA changes in their cancer, he says.

And having more effective, personalized treatment plans means:

Genomics also helps identify certain health risks because these factors play a role in nine out of 10 of theleading causes of death.Knowing youre at risk for diabetes or heart disease could help you take steps to prevent their onset.

Genomic medicine is changing the way doctors approach individualized patient care particularly in the fields of oncology, pharmacology, and rare or genetic diseases.

1.Cancer treatment.Precision genomics improves cancer treatment by providing moretargeted therapiesthat are personalized to each patient.

Intermountain has long been recognized for its role in leading cancer research. By collaborating with other institutions and sharing data, doctors are learning how to best treat cancer. And now Intermountain is leading the charge in precision genomics research.

Through a variety of clinical trials, researchers study how different cancers respond to combinations of targeted treatment and immunotherapy (treatments that stimulate a persons immune system to fight cancer).

2. Matching medication.If youve ever been concerned about the potential side effects of certain medications, pharmacogenomics can help.

Pharmacogenomicsis the study of how genes can affect a persons response to medication. By studying your DNA, doctors can discover which drugs are most likely to work for you and what dosage your body might need. (This includes antidepressants, opioid pain relievers, heart medications, anti-inflammatories, antidiabetics, medications used before and after surgery, and more.) This process is called RxMatch testing. Pinpointing which drugs would be most effective for patients reduces the likelihood of negative side effects and repeat doctor visits.

3. Genetic counseling.Worried that cancer might run in your family? Want to know your chances of passing on conditions to your children?A genetic counselorcan assess your family history and genetic test results to determine if youre at risk of developing certain health conditions.

The National Society of Genetic Counselorssuggests the following as good reasons to see a genetic counselor:

The ultimate goal with each of these is to help patients live longer and better lives. The more you understand about your DNA, the better your chances for a high-quality life.

To see genomics in action, consider one Intermountainpatients story.

In 2013, Telitha Greiner had a colonoscopy that revealed cancer spread to her liver and lungs. A friend suggested she travel to St. George to see Dr. Nadauld, whose focus was extending the lives and quality of life for stage four cancer patients.

The genetic testing done by Dr. Nadauld revealed that one of the cancer drugs I was taking that had particularly painful side effects was not genetically effective, Greiner says. It wasnt doing me any good and caused a very painful skin condition. I am so grateful to know that I dont have to take it anymore and for the state-of-the-art care I am receiving at Intermountain.

Like Greiner, many patients have benefited fromIntermountain Precision Genomics.Its state-of-the-artTheraMap testoffers genetic testing for patients who havent found success with traditional treatment options.

For Nadauld, each individual patient serves as a reminder of how important this research is.

Though a lot of good has come from genetic research, theres still much work to be done. With further research prediction, prevention, and treatment can improve much faster. Thats where you have an opportunity to make a difference.

In order to discover new connections betweengeneticsand human disease, doctors and researchers are asking people to participate in theHerediGene: Population Study.This study is asking for 500,000 participants, including 50,000 children, over the course of five years.

Last year, Dr. Nadauld addressed the importance of HerediGene participation in a podcast episode ofThanks for Asking.

Theres extraordinary interest in this, primarily because it offers the opportunity to understand populations better and to start to predict the health across entire populations, he says. What that means is we could start to predict individuals in a population who might be at risk to get some forms of cancer or other individuals who might be at risk to have a heart attack or a stroke or to develop diabetes. And if we can predict that, then maybe we can work with those individuals to prevent some of those things from happening.

HerediGene participants are helping us piece together clues that will help doctors save lives and that could include your own.

If youre interested in furthering genetic research and benefiting future generations,find a participating location near you.No appointment is necessary. Participation is voluntary and provided at no cost to you.

Genomics is changing the way doctors practice medicine and treat disease. In the coming years, many more people will have access to targeted therapies and medicine designed specifically for them.

But healthcare is not one-size-fits-all. Finding the best healthcare solution for you or your loved ones requires open and honest conversations with your doctor.

If you think precision medicine could be right for you, here are a few suggestedtips for talking with your healthcare provider:

If you have questions or youre interested in learning more,visit the Intermountain Precision Genomics page for patients.

Read the original post:
Healthcare's future resides in genetic research and genomic testing - Utah Business - Utah Business

Foundation Medicine this week announced a new partnership with Epic to integrate its genomic profiling and testing services into its electronic health system.

WHY IT MATTERSCambridge, Massachusetts-based Foundation Medicine offers a suite of genomic profiling assays to identify the molecular alterations of patients' cancers and match them with targeted therapies and clinical trials. With this new collaboration customers will be able to electronically order Foundation tests within the Epic network, directly within the EHR.

The collaboration is aimed at oncology practices, hospitals, academic medical centers and health systems, to enable easy access to clinical and genomic information for more streamlined clinical decision support.

With the new integration, clinical teams can place orders for Foundation's comprehensive genomic profiling tests and receive and view results within their existing EHR workflow. The aim is to also reduce data entry while offering faster actionable insights to help physicians guide treatment planning.

The integration is expected to be available in 2022. Foundation Medicine says it is also partnering with organizations using non-Epic EHRs to meet their own oncology needs.

THE LARGER TRENDThis isn't the only news this week about genomics-focused precision decision support. On Wednesday, AccessDX Holdings, developer of lab diagnostics and CDS tools, announced its acquisition of 2bPrecise which helps health systems advance precision medicine by aggregating genomics from labs and clinical information from EHRs from Allscripts.

Earlier this month, in an interview with Healthcare IT News at HIMSS21, Dr. Robert Bart, chief medical information officer at Pittsburgh-based UPMC, highlighted the necessity of digitized discrete data, integrated into EHR workflows, for precision medicine to work.

"We really think that, when you're moving into the world of pharmacogenomics or genomic medicine, that you really need to embed decision support into your electronic health record," he said.

"And you have to really insist on taking the results only in digital format. So if we get external results from reference labs, we don't want PDFs. We want to actually discrete data, so we can trigger the decision support, as well as provide supporting content for interpretation by our clinicians and the content so the patient can understand what that result means for them."

ON THE RECORD"In order to bring the reality of precision medicine to more cancer patients, we need to simplify the process for getting oncologists access to the genomic insights they need for targeted treatment planning," said Kathleen Kaa, interim chief commercial officer at Foundation Medicine, in a statement about the new Epic integrations. She called it "one of our key efforts to improve the process for ordering our tests so care teams can focus on providing the best treatment for their patients."

Twitter:@MikeMiliardHITNEmail the writer:mike.miliard@himssmedia.comHealthcare IT News is a HIMSS publication.

Read the original:
Foundation Medicine, Epic collaboration focuses on genomics for precision oncology - Healthcare IT News

Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market (2020-2026) report highlights Significant dynamics and in-depth analysis of the market segment with concentrating on factual data, present industry activities, growth opportunities, new product inventions, and market forecast for the future prospective of time along with leading market players, market study based on several regions, and extensive product. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market report can function as an assistive reference point for helping individuals as well as businesses from this segment.

The report on Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market comprises an in-depth analysis of key global developments that will be beneficial to businesses operating in this industry. The report delivers a clear understanding of the major trends and forthcoming market prospects to facilitate the making of effective business strategies.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/5146

The study identifies the opportunities and growth drivers that will impact the remuneration scale of the industry over the analysis period. It also entails the threats and challenges tackled by the industry along with solutions to subdue their impact.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/5146

The report offers a comparison of present and past market outlook to deduce the growth rate of this industry vertical over the study period. Besides, it evaluates the COVID-19 pandemic impact on overall and regional markets to determine methodologies that can potentially yield significant returns for industry participants.

Main highlights from table of contents:

Product landscape

Application scope

Geographical terrain

Competitive outlook

In summary, the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market assessment has been performed at a granular level through various segmentations, while keeping track of other crucial aspects like supply chain and sales channel comprising of details about the downstream buyers, upstream suppliers, raw materials, and distributors in the industry.

Key Benefits For Stakeholders

The Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market report provides extensive qualitative insights on the potential and niche segments or regions exhibiting favorable growth.

The report provides an extensive analysis of the current and emerging market trends and opportunities in the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market.

A comprehensive analysis of the factors that drive and restrict the growth of the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market is provided.

An extensive analysis of the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market is conducted by following key product positioning and monitoring the top competitors within the market framework.

The report provides a detailed qualitative and quantitative analysis of current trends and future estimations that help evaluate the prevailing market opportunities.

Request Customization on This Report @ https://www.theresearchprocess.com/request-for-customization/5146

See original here:
Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market: Development Factors and Investment Analysis by Leading Manufacturers -...

Pharmacogenetics, or precision medicine, is still new to many pediatric providers despite its documented benefits, according to an article the Sanford Childrens Genomic Medicine Consortium published recently in The Pharmacogenomics Journal.

Pharmacogenetics uses a persons DNA to help providers choose the best medicine and dosage of medicine. And there are plenty of opportunities to use genetic traits in pediatrics, the group wrote.

Theres evidence that pharmacogenetics benefit pediatric oncology, pain management, organ transplantation, and immunosuppression, according to the journal article. Additionally, advances in technology have made it easier to study complete genomes, and providers can use that information to improve health care for children.

Ten hospitals have signed on to the consortium to rapidly integrate genetics and genomics into primary and specialty pediatric care.

Above all, the mission of the consortium is to efficiently manage resources in genetics and genomics, perform cutting-edge research and education and bring genomic medicine into pediatric practice. This will help set the standard for precision medicine in childrens health care.

The 10 member hospitals are:

A previous innovation project funded by the consortium was a study of the outcomes of rapid whole genomic sequencing in critically ill newborn infants. Another previous study evaluated the routine use of an extensive, pediatric-focused, next generation sequencing panel in the diagnosis of childhood cancers.

Posted In Children's, Company News, Genetics

Originally posted here:
Sanford genetics group shares benefits of custom kids' care - Sanford Health News

This report studies the Sports and Fitness Genomics and Pharmacogenomics Market with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. Find the complete Sports and Fitness Genomics and Pharmacogenomics Market analysis segmented by companies, region, type and applications in the report.

The report offers valuable insight into the Sports and Fitness Genomics and Pharmacogenomics market progress and approaches related to the Sports and Fitness Genomics and Pharmacogenomics market with an analysis of each region. The report goes on to talk about the dominant aspects of the market and examine each segment.

Key Players: GeneDx, Assurex Health, 23andMe, Teva Pharmaceutical Industries, Future Science Group, Myriad Genetics, Pathway Genomics, and GeneTech

The final report will add the analysis of the Impact of Covid-19 in this report Sports and Fitness Genomics and Pharmacogenomics industry.

Get a Free Sample Copy @ https://www.reportsandmarkets.com/sample-request/global-sports-and-fitness-genomics-and-pharmacogenomics-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread?utm_source=neighborwebsj&utm_medium=36

The global Sports and Fitness Genomics and Pharmacogenomics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Sports and Fitness Genomics and Pharmacogenomics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2020-2026.

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Research objectives:

To study and analyze the global Sports and Fitness Genomics and Pharmacogenomics market size by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2026.

To understand the structure of Sports and Fitness Genomics and Pharmacogenomics market by identifying its various sub segments.

Focuses on the key global Sports and Fitness Genomics and Pharmacogenomics players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Sports and Fitness Genomics and Pharmacogenomics with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the size of Sports and Fitness Genomics and Pharmacogenomics submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.

Table of Contents: Sports and Fitness Genomics and Pharmacogenomics Market

Chapter 1: Overview of Sports and Fitness Genomics and Pharmacogenomics Market

Chapter 2: Global Market Status and Forecast by Regions

Chapter 3: Global Market Status and Forecast by Types

Chapter 4: Global Market Status and Forecast by Downstream Industry

Chapter 5: Market Driving Factor Analysis

Chapter 6: Market Competition Status by Major Manufacturers

Chapter 7: Major Manufacturers Introduction and Market Data

Chapter 8: Upstream and Downstream Market Analysis

Chapter 9: Cost and Gross Margin Analysis

Chapter 10: Marketing Status Analysis

Chapter 11: Market Report Conclusion

Chapter 12: Research Methodology and Reference

Key questions answered in this report

What will the market size be in 2026 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

Get complete Report @ https://www.reportsandmarkets.com/sample-request/global-sports-and-fitness-genomics-and-pharmacogenomics-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread?utm_source=neighborwebsj&utm_medium=36

About Us:

Reports and Markets is not just another company in this domain but is a part of a veteran group called Algoro Research Consultants Pvt. Ltd. It offers premium progressive statistical surveying, market research reports, analysis & forecast data for a wide range of sectors both for the government and private agencies all across the world. The database of the company is updated on a daily basis. Our database contains a variety of industry verticals that include: Food Beverage, Automotive, Chemicals and Energy, IT & Telecom, Consumer, Healthcare, and many more. Each and every report goes through the appropriate research methodology, Checked from the professionals and analysts.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

https://neighborwebsj.com/

See the article here:
Sports and Fitness Genomics and Pharmacogenomics Market Size And Forecast (2020-2026)| With Post Impact Of Covid-19 By Top Leading Players- GeneDx,...

Drug Discovery Technologies Industry Market Forecast 2029: Revenue, Size & Growth

Global Drug Discovery Technologies Industry MarketForecast till 2029research includes reliable economic, international, and country-level forecasts and analysis. It offers a holistic view of the competitive market and thorough analyses of the supply chain to help companies identify closely significant trends in the company practices seen in the sector. Major Companies listed in this Reports areLuminex Corporation, Bayer Healthcare AG, Novartis AG, Agilent Technologies, Inc, Affymetrix Inc., Astrazeneca plc, Albany Molecular Research Inc., GE Healthcare Ltd., Abbott Laboratories, Inc., Arqule Inc..

Free Sample Report & Pie Charts Available@jcmarketresearch.com/report-details/1139660/sample

Regional Breakout for Drug Discovery Technologies Industry Market: North America XXX million $, Europe XXX million $, Asia XXX million $ & Rest of World.

OverviewDrug Discovery Technologies Industry Market including Types & Application:

North America:United States, Canada, and MexicoSouth & Central America:Argentina, Chile, and BrazilMiddle East & Africa:Saudi Arabia, UAE, Turkey, Egypt and South AfricaEurope:UK, France, Italy, Germany, Spain, and Russia

Application: Biopharmaceutical companies, Pharmaceutical companies, Research institutes, Biotech companies

Types:Biochips, High throughput screening, Pharmacogenomics, Genomics, Bioanalytical instruments, Bioinformatics, Nanotechnology, Others (RNAi, combinatorial chemistry)

Drug Discovery Technologies Industry Market Leading Competition:In this section, the report provides information on Competitive situations and trends including merger and acquisition and expansion, market shares of the top ten players, and market concentration rate. Readers could also be provided with production, revenue, and average price shares by manufacturers.

Get Special Discount in Covid-19 @jcmarketresearch.com/report-details/1139660/discount

Research Methodology:

The market engineering process uses a top-down and bottom-up approach and several data triangulation methods to evaluate and validate the size of the entire market and other dependent sub-markets listed in Drug Discovery Technologies Industry report. Numerous qualitative and quantitative analyzes have been conducted in the market engineering process to list key information / insights. The major players in the market were identified through the second survey and the market rankings were determined through the first and second surveys.

Primary Research:

During the first survey, we interviewed various key sources of supply and demand to obtain qualitative and quantitative information related to Drug Discovery Technologies Industry report. Key supply sources include key industry participants, subject matter specialists from key companies, and consultants from several major companies and organizations active in the digital signage market.

Secondary Research:

The second study was conducted to obtain key information on the supply chain of the Drug Discovery Technologies Industry industry, the markets currency chain, pools of major companies, and market segmentation, with the lowest level, geographical market, and technology-oriented perspectives. Secondary data was collected and analyzed to reach the total market size, which was verified by the first survey.

Global Drug Discovery Technologies Industry Market Detailed study of each point:

TheDrug Discovery Technologies Industry Marketstudy offers a comprehensive overview of the current market and forecasts by 2020-2029 to help identify emerging business opportunities on which to capitalize.

The report provides an in-depth review of industry dynamics in Drug Discovery Technologies Industry, including existing and potential developments to represent prevailing consumer pockets of investment.

The report provides details concerning key drivers, constraints and opportunities and their effect on the Drug Discovery Technologies Industry market.

Industry players Luminex Corporation, Bayer Healthcare AG, Novartis AG, Agilent Technologies, Inc, Affymetrix Inc., Astrazeneca plc, Albany Molecular Research Inc., GE Healthcare Ltd., Abbott Laboratories, Inc., Arqule Inc. strategic analysis and industry position in the global Drug Discovery Technologies Industry market;

The report elaborates on the SWOT analysis and Porters Five Forces model.

The market-study value chain review gives a good view of the positions of the stakeholders.

GetCustomized Report Toc @:jcmarketresearch.com/report-details/1139660/enquiry

Major Highlights of Drug Discovery Technologies Industry Market in Covid-19 pandemic covered in report:

Market Competition by key manufacturers in the Drug Discovery Technologies Industry industry. Discussed Sourcing strategies, industrial chain information and downstream buyers data. Distributors and traders on Drug Discovery Technologies Industry marketing strategy analysis focusing on region wise needs in covid-19 pandemic. Vendors who are providing a wide range of product lines and intensifying the competitive scenario in Drug Discovery Technologies Industry covid-19 crisis. Also highlights of the key growth sectors of Drug Discovery Technologies Industry market and how they will perform in coming years.

Buy Full Copy Global Drug Discovery Technologies Industry Report 2029 @jcmarketresearch.com/checkout/1139660

** The demand is measured on the basis of the weighted average sale price (WASP), which requires the manufacturers taxes. The currency conversions that were used to construct this study were determined using a given annual average rate of currency exchange from 2020.

About Author:

JCMRglobal research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.

Contact Us:https://jcmarketresearch.com/contact-us

JC MARKET RESEARCH

Mark Baxter (Head of Business Development)

Phone:+1 (925) 478-7203

Email:[emailprotected]

Connect with us at LinkedIn

http://www.jcmarketresearch.com

See the article here:
Drug Discovery Technologies Industry Market including top key players Luminex Corporation, Bayer Healthcare AG, Novartis AG - PRnews Leader

This contemporary, modern market research compilation is a systematic overview of the overall market status and structure prevalent in global Sports and Fitness Genomics and Pharmacogenomics market and their rampant implications upon holistic growth trajectory and further probabilities in the near future. The report is based on extensive primary and secondary research initiatives and the insights thus achieved have been stacked systematically aided by several graphs, tables and charts to encourage seamless comprehension. The report sheds ample light into both past and current developments to infer futuristic probabilities. Relevant understanding on market prognosis, trends, policy updates and current development statistics have all been highlighted in thorough detail for quick deductions and subsequent investment discretion by Orbis Pharma Reports.

Get sample copy of [emailprotected] https://www.orbispharmareports.com/sample-request/91270

Major Company Profiles operating in the Sports and Fitness Genomics and Pharmacogenomics Market:

Assurex HealthTeva Pharmaceutical IndustriesFuture Science GroupPathway Genomics23andMeGeneDxMyriad GeneticsGeneTechMajor Types CoveredMicroarraySequencingPolymerase Chain ReactionOthers

By the product type, the market is primarily split into

MicroarraySequencingPolymerase Chain ReactionOthers

By the application, this report covers the following segments

OncologyCardiologyNeurological DisordersOthers

Browse the complete report @ https://www.orbispharmareports.com/2015-2027-global-sports-and-fitness-genomics-and-pharmacogenomics-industry-market-research-report-segment-by-player-type-application-marketing-channel-and-region/

Regional Overview:This versatile research report presentation on global Sports and Fitness Genomics and Pharmacogenomics market, presented by Orbis Pharma Reports has maintained highest parameters of research practices to unravel crucial details. Holistic geographical diversifications have been carefully analyzed and prominent growth centers have been categorically flagged to maintain uniform growth trends.Besides entailing region-specific details, country-wise detailing have also been included to encourage rapid decision making. For maximum reader discretion and subsequent investment decisions, this report on global Sports and Fitness Genomics and Pharmacogenomics market as assessed by Orbis Pharma Reports reveals Germany, France, Italy, UK as ideal growth hotspots, followed by American growth hubs such as Mexico, Brazil, US and Canada. MEA countries and APAC nations have also been thoroughly scanned to understand growth patterns, competition intensity as well as vendor activities across these growth points.

For Any Query on the Sports and Fitness Genomics and Pharmacogenomics Market: https://www.orbispharmareports.com/enquiry-before-buying/91270

Decoding Segment Specifications:The report by Orbis Pharma Reports on global Sports and Fitness Genomics and Pharmacogenomics market encourages complete stratification of the market in terms of segments to understand growth patterns. All prominent segments highlighted in the report have been assessed based on set parameters such as capital diversion, inventory management as well as utility diversification, besides exploring supply chain developments to understand segment potential in growth progression. Each of the segment identified has been assessed on the basis of various market parameters to explore growth projections and likelihood. The report is based on complete SWOT and PESTEL assessment, followed by PORTERs Five Forces assessment and evaluation of all DROT factors. These details are highly crucial to encourage appropriate investment decisions on the part of inquisitive readers and aspirational investors.Orbis Pharma Reports also sketches the prevalent competition landscape, isolating frontline players as well as their growth proficient business decisions. Based on these business decisions, this report helps investors to deliver lucrative business decisions.

About Us :

At Orbispharma we curate the most relevant news stories, features, analysis and research reports on the important challenges undertaken by the pharmaceutical and related sectors. Our editorial philosophy is to bring you sharp, focused and informed perspective of industries, the end users and application of all upcoming trends into the pharma sector. Orbispharma believes in conversations that can bring a change in one of the most crucial economic sectors in the world. With these conversations we wish our customers to make sound business decisions with right business intelligence.

Contact Us :

Read the original here:
Sports and Fitness Genomics and Pharmacogenomics Industry Market 2021 In-depth Analysis, Growth with Forecast 2027:Assurex Health, Teva Pharmaceutical...

This article was originally published here

Patterns (N Y). 2020 Jul 2;1(5):100065. doi: 10.1016/j.patter.2020.100065. eCollection 2020 Aug 14.

ABSTRACT

High-throughput drug screens in cancer cell lines test compounds at low concentrations, thereby enabling the identification of drug-sensitivity biomarkers, while resistance biomarkers remain underexplored. Dissecting meaningful drug responses at high concentrations is challenging due to cytotoxicity, i.e., off-target effects, thus limiting resistance biomarker discovery to frequently mutated cancer genes. To address this, we interrogate subpopulations carrying sensitivity biomarkers and consecutively investigate unexpectedly resistant (UNRES) cell lines for unique genetic alterations that may drive resistance. By analyzing the GDSC and CTRP datasets, we find 53 and 35 UNRES cases, respectively. For 24 and 28 of them, we highlight putative resistance biomarkers. We find clinically relevant cases such as EGFRT790M mutation in NCI-H1975 or PTEN loss in NCI-H1650 cells, in lung adenocarcinoma treated with EGFR inhibitors. Interrogating the underpinnings of drug resistance with publicly available CRISPR phenotypic assays assists in prioritizing resistance drivers, offering hypotheses for drug combinations.

PMID:33205120 | PMC:PMC7660407 | DOI:10.1016/j.patter.2020.100065

See the original post here:
Identification of Intrinsic Drug Resistance and Its Biomarkers in High-Throughput Pharmacogenomic and CRISPR Screens - DocWire News

The "Global Precision Medicine Market: Focus on Ecosystem, Technology, Application, Country Data (21 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Global Precision Medicine Market to Reach $278.61 Billion by 2030

Precision medicine refers to the medicine developed as per an individual's genetic profile. It provides guidance regarding the prevention, diagnosis, and treatment of diseases. The segmentation of the population is done depending on the genome structure of the individuals and their compatibility with a specific drug molecule.

In the precision medicine market, the application of molecular biology is to study the cause of a patient's disease at the molecular level, so that target-based therapies or individualized therapies can be applied to cure the patient's health-related problems.

This industry is gaining traction due to the increasing awareness about healthcare among individuals, integration of smart devices such as smartphones and tablets into healthcare, and increasing collaborations and agreements of IT firms with the diagnostics and biopharmaceutical companies for the development of precision diagnostic tools.

Within the research report, the market is segmented on the basis of product type, ecosystem application, and region, which highlight value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide 360-degree coverage of the domain.

Key Topics Covered:

1 Product Definition

2 Research Scope

3 Research Methodology

4 Global Precision Medicine Market Overview

4.1 Market Definition

4.2 Precision Medicine: A Frontier in the Genesis of Patient-centric Medicine

4.3 Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy

4.4 Initiatives and Programs

4.5 Precision Medicine: Enabling Technologies and Applications

4.5.1 Innovators

4.5.1.1 3D DNA Printing

4.5.1.1.1 Introduction

4.5.1.1.2 Role of 3D DNA Printing

4.5.1.2 RNA-Seq

4.5.1.2.1 Introduction

4.5.1.2.2 Role of RNA-Seq in Precision Medicine

4.5.1.2.3 Key Players

4.5.1.3 4D Molecular Imaging

4.5.1.3.1 Introduction

4.5.1.3.2 Role of 4D Molecular Imaging in Precision Medicine

4.5.1.3.3 Key Players

4.5.2 Early Adopters

4.5.2.1 CRISPR

4.5.2.1.1 Introduction

4.5.2.1.2 Role of CRISPR in Precision Medicine

4.5.2.1.3 Key Players

4.5.2.2 Blockchain

4.5.2.3 Imaging Informatics

4.5.3 Early Majority

4.5.3.1 Artificial Intelligence (AI)

4.5.3.2 Circulating Free DNA (cfDNA)

4.5.3.3 Big Data

4.5.3.4 Next-Generation Sequencing (NGS)

4.5.3.5 Health Informatics

4.5.3.6 Bioinformatics

4.5.4 Late Majority

4.5.4.1 Polymerase Chain Reactions (PCR)

4.5.4.2 Microarray

4.6 COVID-19 Impact on the Global Precision Medicine Market

5 Market Dynamics

5.1 Overview

5.2 Market Drivers

5.2.1 Advancement of Sequencing Technologies

5.2.2 Rising Prevalence of Chronic Diseases

5.2.3 Growing Demand for Preventive Care

5.2.4 Shifting the Significance in Medicine, from Reaction to Prevention

5.2.5 Reducing Adverse Drug Reactions Through Pharmacogenomics Test

5.2.6 Potential to Reduce the Overall Healthcare Cost Across the Globe

5.3 Market Restraints

5.3.1 Unified Framework for Data Integration

5.3.2 Limited Knowledge about Molecular Mechanism/ Interaction

5.3.3 Lack of Robust Reimbursement Landscape

5.3.4 Regulatory Hurdles

5.4 Market Opportunities

5.4.1 Targeted Gene Therapy

5.4.2 Expansion into the Emerging Markets

5.4.3 Collaboration and Partnerships Across Value Chain to Accelerate the Market Entry

6 Industry Insights

6.1 Patent Analysis

6.2 Legal Requirements and Regulations

6.3 Pipeline Analysis

6.4 Legal Requirements and Framework by the FDA

6.5 Legal Requirements and Framework by the EMA

6.6 Legal Requirements and Framework by the MHLW

7 Competitive Landscape

7.1 Synergistic Activities

7.1.1 Product launches, Enhancements, and Upgradation

7.1.2 Product Approvals

7.1.3 Mergers and Acquisitions

7.1.4 Business Expansion

7.2 Market Share Analysis

7.2.1 Market Share Analysis by Applied Sciences, 2019

7.2.2 Market Share Analysis by Precision Diagnostics, 2019

7.2.3 Market Share Analysis by Precision Therapeutics, 2019

7.2.4 Market Share Analysis by Digital Health and IT, 2019

8 Global Precision Medicine Market (by Ecosystem)

8.1 Overview

8.2 Applied Sciences

8.2.1 Genomics

8.2.2 Global Precision Medicine Genomics Market (by Technology)

8.2.2.1 Polymerase Chain Reaction (PCR)

8.2.2.2 Next-Generation Sequencing (NGS)

8.2.2.3 Genome Editing

8.2.2.4 Other Technologies

8.2.3 Pharmacogenomics

8.2.4 Other Applied Sciences

8.3 Precision Diagnostics

8.3.1 Molecular Diagnostics (MDx)

8.3.2 Global Precision Medicine Molecular Diagnostics Market (by Type)

8.3.2.1 Non-Invasive Prenatal Testing (NIPT)

8.3.2.2 Companion Diagnostics

8.3.2.3 Liquid Biopsy

8.3.2.4 Other Molecular Diagnostics

Visit link:
Global Precision Medicine Market 2020-2030: Focus on Ecosystem, Technology, Application, and Competitive Landscape - ResearchAndMarkets.com - Benzinga

Dublin, Nov. 19, 2020 (GLOBE NEWSWIRE) -- The "Genomic Cancer Panel and Profiling Markets by Cancer and Germline/Somatic Type with Screening Potential Market Size, Customized Forecasting/Analysis, and Executive and Consultant Guides 2021-2025" report has been added to ResearchAndMarkets.com's offering.

This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help understand test pricing in detail.

Forecast demand for new testing regimes or technologies. Make research investment decisions. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth.

Cancer Gene Panels and Genomic Profiling are quickly changing the diagnosis and treatment of cancers. The market is moving out of a specialized niche and going mainstream as Oncologists begin routinely using information on the hundreds of genes related to cancer. The market is exploding as physicians use all the information they can get in the battle against cancer. And there is a lot of information to be had. But the COVID-19 Pandemic has impacted the market.

Comprehensive panels, genomic profiling, high-risk breast cancer panels. Learn all about how players are jockeying for position in a market that is being created from scratch. And some players are already taking the lead. It is a dynamic market situation with enormous opportunity where the right diagnostic with the right support can command premium pricing. And the science is developing at the same time creating new opportunities with regularity. And the cost of sequencing continues to fall.

The report includes detailed breakouts for 18 Countries and 4 Regions.

Key Topics Covered:

Cancer Panel Market - Strategic Situation Analysis & COVID Update

1. Introduction and Market Definition 1.1 What are Cancer Gene Panels and Profiling? 1.2 The Sequencing Revolution 1.3 Market Definition 1.4 Methodology 1.5 A Spending Perspective on Clinical Laboratory Testing 1.5.1 An Historical Look at Clinical Testing

2. Market Overview 2.1 Players in a Dynamic Market 2.1.1 Academic Research Lab 2.1.2 Diagnostic Test Developer2.1.3 Instrumentation Supplier 2.1.4 Distributor and Reagent Supplier 2.1.5 Independent Testing Lab2.1.6 Public National/regional lab 2.1.7 Hospital lab 2.1.8 Physician Office Labs 2.1.9 Audit Body 2.1.10 Certification Body2.2 Oncogenomics2.2.1 Carcinogenesis2.2.2 Chromosomes, Genes and Epigenetics 2.2.2.1 Chromosomes 2.2.2.2 Genes 2.2.2.3 Epigenetics 2.2.3 Cancer Genes 2.2.4 Germline vs Somatic 2.2.5 Gene Panels, Single Gene Assays and Multiplexing 2.2.6 Genomic Profiling 2.2.7 The Comprehensive Assay 2.2.8 Changing Clinical Role 2.2.9 The Cancer Screening Market Opportunity2.3 Cancer Management vs. Diagnosis 2.3.1 The Role of Risk Assessment 2.3.2 Diagnosis 2.3.3 Managing 2.3.4 Monitoring 2.4 Phases of Adoption - Looking into The Future 2.5 Structure of Industry Plays a Part 2.5.1 Hospital Testing Share 2.5.2 Economies of Scale2.5.2.1 Hospital vs. Central Lab 2.5.3 Physician Office Lab's 2.5.4 Physician's and POCT

3. Market Trends3.1 Factors Driving Growth3.1.1 Level of Care 3.1.2 Companion Dx 3.1.3 Immuno-oncology 3.1.4 Liability3.1.5 Aging Population3.2 Factors Limiting Growth3.2.1 State of knowledge3.2.2 Genetic Blizzard. 3.2.3 Protocol Resistance3.2.4 Regulation and coverage 3.3 Instrumentation and Automation 3.3.1 Instruments Key to Market Share 3.3.2 Bioinformatics Plays a Role 3.4 Diagnostic Technology Development3.4.1 Next Generation Sequencing Fuels a Revolution 3.4.2 Single Cell Genomics Changes the Picture 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment3.4.4 CGES Testing, A Brave New World 3.4.5 Biochips/Giant magnetoresistance based assay

4. Cancer Panels & Profiles Recent Developments 4.1 Recent Developments - Importance and How to Use This Section 4.1.1 Importance of These Developments 4.1.2 How to Use This Section

5. Profiles of Key Players

6. The Global Market for Cancer Gene Panels and Profiles

7. Global Cancer Gene Panels & Profiles Markets - By Type of Cancer 7.1 Comprehensive Panels & Profiles 7.2 Breast Cancer Gene Testing 7.3 Colorectal Cancer Gene Testing7.4 Gynecological Cancer Gene Testing 7.5 Blood Cancer Gene Testing 7.6 Prostate Cancer Gene Testing 7.7 Lung Cancer Gene Testing7.8 Other Cancer Gene Testing

8. Global Cancer Gene Testing Markets - Germline and Somatic 8.1 Global Market Somatic 7.3 Global Market Germline

9. Potential Market Opportunity Sizes 9.1 Potential Cancer Screening by Country: Lung, Breast & Colorectal 9.2 Potential Cancer Screening by Country: Prostate, Other Cancer & All Cancer 9.3 Potential Market Size - Cancer Diagnosis 9.4 Potential Market Size - Therapy Selection

Appendices

For more information about this report visit https://www.researchandmarkets.com/r/5bx3ai

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

More:
Global Genomic Cancer Panel and Profiling Markets Report 2021-2025: The Market is Moving Out of a Specialized Niche and Going Mainstream -...